Related Experiment Video
Updated: May 30, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab in the treatment of high-grade gliomas: an overview
Saroj Kunnakkat1, Ashwatha Narayana
1Department of Radiation Oncology, New York University Langone Medical Center, 550 1st Ave., New York, NY 10016, USA.
Abstract:
Angiogenesis is a process that is integral to the pathogenesis of high-grade gliomas. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor has emerged as an important therapeutic agent. Data from clinical trials in both recurrent and newly-diagnosed gliomas have shown improved radiological responses and quality of life with acceptable morbidity. However, an improvement in overall survival has not yet been seen and there are concerns on possible change in the pattern of relapse following therapy. Several unanswered questions remain including the dose, timing and sequencing that warrant further research.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

